Two Dose Regimens of Nifedipine for Management of Preterm Labor: A Randomized Controlled Trial

 

 Buy Article Permissions and Reprints

ABSTRACT

We compared two dose regimens of tocolytic oral nifedipine. Women with singleton pregnancies admitted in preterm labor (24 to 34 weeks) were randomized to high-dose (HD) nifedipine (n = 49; 20 mg loading dose, repeated in 30 minutes, daily 120 to 160 mg slow-release nifedipine for 48 hours followed by 80 to 120 mg daily until 36 weeks) or low-dose (LD) nifedipine (n = 53; 10 mg, up to four doses every 15 minutes, daily 60 to 80 mg slow-release nifedipine for 48 hours followed by 60 mg daily until 36 weeks). Uterine quiescence at 48 hours (primary outcome); delivery at 48 hours, 34 and 37 weeks; and recurrent preterm labor were similar. Gestational age at delivery was higher in HD (36.0 ± 2.8 versus 34.7 ± 3.7 weeks, p = 0.049). Rescue treatment was needed more in LD (24.5 versus 50.9%, odds ratio = 0.3; 95% confidence interval 0.1 to 0.7). Maternal adverse effects, birth weight, intensive care nursery admission, and composite neonatal morbidity were similar. However, neonatal mechanical ventilation was needed less and nursery stay was shorter in HD. HD nifedipine does not seem to have an advantage over LD in achieving uterine quiescence at 48 hours. Further studies should address the optimal dose and formulation of tocolytic nifedipine.

REFERENCES

• 1 Martin J A, Hamilton B E, Sutton P D et al.. Births: final data for 2005.  Natl Vital Stat Rep. 2007;  56 1-103
  PubMedGoogle Scholar
• 2 Lewis D F. Magnesium sulfate: the first-line tocolytic.  Obstet Gynecol Clin North Am. 2005;  32 485-500
  CrossrefPubMedGoogle Scholar
• 3 Crowther C A, Hiller J E, Doyle L W. Magnesium sulphate for preventing preterm birth in threatened preterm labour.  Cochrane Database Syst Rev. 2002;  CD001060
  PubMedGoogle Scholar
• 4 Nassar A H, Sakhel K, Maarouf H, Naassan G R, Usta I M. Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis.  Acta Obstet Gynecol Scand. 2006;  85 1099-1103
  PubMedGoogle Scholar
• 5 Grimes D A, Nanda K. Magnesium sulfate tocolysis: time to quit.  Obstet Gynecol. 2006;  108 986-989
  Google Scholar
• 6 Mittendorf R, Dambrosia J, Pryde P G et al.. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants.  Am J Obstet Gynecol. 2002;  186 1111-1118
  CrossrefPubMedGoogle Scholar
• 7 Anotayanonth S, Subhedar N V, Garner P, Neilson J P, Harigopal S. Betamimetics for inhibiting preterm labour.  Cochrane Database Syst Rev. 2004;  CD004352
  PubMedGoogle Scholar
• 8 Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour.  Cochrane Database Syst Rev. 2005;  CD004452
  PubMedGoogle Scholar
• 9 King J F, Flenady V J, Papatsonis D N, Dekker G A, Carbonne B. Calcium channel blockers for inhibiting preterm labour.  Cochrane Database Syst Rev. 2003;  CD002255
  PubMedGoogle Scholar
• 10 Duley L M. Tocolytic drugs for women in preterm labour. RCOG (Royal College of Obstetricians and Gynaecologists, UK) Guideline No 1B. London; RCOG 2002
  Google Scholar
• 11 Carr D B, Clark A L, Kernek K, Spinnato J A. Maintenance oral nifedipine for preterm labor: a randomized clinical trial.  Am J Obstet Gynecol. 1999;  181 822-827
  CrossrefPubMedGoogle Scholar
• 12 PATH, World Health Organization, United Nations Population Fund .Essential medicines for reproductive health: guiding principles for their inclusion on national medicines lists. Seattle, WA; PATH 2006 http://Available at www.who.int/reproductive-health/publications/essential_medicines/emls_guidingprinciples.pdf
  Google Scholar
• 13 Tsatsaris V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis.  Obstet Gynecol. 2001;  97 840-847
  CrossrefPubMedGoogle Scholar
• 14 Glock J L, Morales W J. Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: a randomized study.  Am J Obstet Gynecol. 1993;  169 960-964
  PubMedGoogle Scholar
• 15 Papatsonis D N, van Geijn H P, Bleker O P, Ader H J, Dekker G A. Hemodynamic and metabolic effects after nifedipine and ritodrine tocolysis.  Int J Gynaecol Obstet. 2003;  82 5-10
  CrossrefPubMedGoogle Scholar
• 16 van Veen A J, Pelinck M J, van Pampus M G, Erwich J J. Severe hypotension and fetal death due to tocolysis with nifedipine.  BJOG. 2005;  112 509-510
  PubMedGoogle Scholar
• 17 Ferguson 2nd J E, Schutz T, Pershe R, Stevenson D K, Blaschke T. Nifedipine pharmacokinetics during preterm labor tocolysis.  Am J Obstet Gynecol. 1989;  161 1485-1490
  CrossrefPubMedGoogle Scholar
• 18 Guclu S, Saygili U, Dogan E, Demir N, Baschat A A. The short-term effect of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms.  Ultrasound Obstet Gynecol. 2004;  24 761-765
  PubMedGoogle Scholar
• 19 Economy K E, Abuhamad A Z. Calcium channel blockers as tocolytics.  Semin Perinatol. 2001;  25 264-271
  PubMedGoogle Scholar
• 20 van Geijn H P, Lenglet J E, Bolte A C. Nifedipine trials: effectiveness and safety aspects.  BJOG. 2005;  112 79-83
  CrossrefPubMedGoogle Scholar
• 21 Nassar A H, Ghazeeri G, Usta I M. Nifedipine-associated pulmonary complications in pregnancy.  Int J Gynaecol Obstet. 2007;  97 148-149
  CrossrefPubMedGoogle Scholar
• 22 Verhaert D, Van Acker R. Acute myocardial infarction during pregnancy.  Acta Cardiol. 2004;  59 331-339
  CrossrefPubMedGoogle Scholar
• 23 Parasuraman R, Gandhi M M, Liversedge N H. Nifedipine tocolysis associated atrial fibrillation responds to DC cardioversion.  BJOG. 2006;  113 844-845
  PubMedGoogle Scholar
• 24 Ugwumadu A. Nifedipine-tocolysis-associated atrial fibrillation responds to DC cardioversion.  BJOG. 2007;  114 236-237
  PubMedGoogle Scholar
• 25 Taslimi M M, Sibai B M, Amon E, Taslimi C K, Herrick C N. A national survey on preterm labor.  Am J Obstet Gynecol. 1989;  160 1352-1357
  PubMedGoogle Scholar

Anwar H NassarM.D. 

Department of Obstetrics and Gynecology, American University of Beirut Medical Center

PO Box: 113-6044/B36, Beirut-Lebanon

Email: an21@aub.edu.lb